Novartis Investigative Site

Germering 82110

0 studies enrolling now · 5 studies all time

What they study most

Cushing's Disease, Hereditary Periodic Fevers, Psoriatic Arthritis, Spondylitis, Ankylosing

Studies at this site

• Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis — Completed
• Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis — Completed
• 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis — Completed
• Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease — Completed
• Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers — Completed